NeoTYPE® DNA & RNA - Lung
Use
NeoTYPE® DNA & RNA - Lung is a targeted next-generation sequencing profile designed to detect a wide range of genetic alterations in 50 genes, including single nucleotide variants, insertions/deletions, copy number variants, RNA fusions, and splice variants. It aids in identifying prognostic information, susceptibility or resistance to therapies, and clinical trials opportunities for lung cancer patients. The test also includes assessments of microsatellite instability and tumor mutation burden, with optional PD-L1 immunohistochemistry for NSCLC.
Special Instructions
Testing requires >20% tumor content and >5 mm2 of tissue. When submitting unstained slides, ensure a sufficient number are provided based on tissue area. Cold packs should be used during transport to maintain sample integrity. For further inquiries, contact NeoGenomics Client Services.
Limitations
Samples that do not meet the required tumor percentage or surface area may lead to compromised or incomplete results. Indeterminate MSI results may reflex to additional PCR testing. Insufficient samples may lead to incomplete DNA or RNA analyses, and alternate CPT codes may apply. Accurate CPT coding is the responsibility of the billing party, and queries should be directed to payors.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Mutation
Fusion
Result Turnaround Time
8-10 days
Related Documents
For more information, please review the documents below
Specimen
Tissue
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
A block is preferred for testing: >20% tumor and >5 mm2 of tissue surface area for NGS (~500 tumor cells). If submitting 5-micron unstained slides, send 10-20 slides based on tissue area, plus additional slides for PD-L1 testing.
Storage Instructions
Use cold pack for transport, ensuring it is not in direct contact with the specimen.